hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo’ Khan talked with Proactive about the company’s trading update for the first half of 2025 and shared insights into its outlook and operational progress. Khan reported first-half revenue of £24 million, highlighting growth from diversified services, particularly in laboratory operations under hLab and through the newly acquired Clinical Research Services (CRS). EBITDA margins stood at around 12%, aided by operational efficiencies and upfront non-refundable fees f ...